文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

间充质干细胞治疗COVID-19相关中重度急性呼吸窘迫综合征的随机试验

A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01
一句话结论对COVID-19相关中重度ARDS机械通气患者,异体间充质干细胞两次输注安全,但未改善30天生存或60天无呼吸机生存。

研究纳入COVID-19相关中重度呼吸衰竭的机械通气患者,随机接受两次2百万细胞/kg的异体间充质干细胞输注或假输注,均联合标准治疗。主要终点30天死亡率在细胞组为37.5%(42/112),对照组为42.7%(47/110),RR 0.88(95%CI 0.64-1.21;P=0.43),无显著差异。60天内无呼吸机生存天数中位秩细胞组117.3 vs 对照组102.0,无显著差异;30天ARDS缓解或改善比例细胞组49.0%(51/104)vs 对照组43.4%(46/106),OR 1.36(95%CI 0.57-3.21)。无输注相关毒性,30天总体严重不良事件相似。

要点

  • 30天死亡率细胞组37.5%(42/112)vs 对照组42.7%(47/110),RR 0.88(95%CI 0.64-1.21;P=0.43),无显著差异。
  • 60天内无呼吸机生存天数中位秩细胞组117.3(IQR 60.0-169.5)vs 对照组102.0(IQR 54.0-162.5),无显著差异。
  • 30天ARDS缓解或改善比例细胞组49.0%(51/104)vs 对照组43.4%(46/106),OR 1.36(95%CI 0.57-3.21)。
  • 无输注相关毒性,30天总体严重不良事件两组相似。
  • 数据与安全监察委员会在第三次中期分析时建议停止入组,因预设死亡率从40%降至23%的效应不太可能达到(n=222/计划300)。

适用人群与场景

  • COVID-19相关中重度呼吸衰竭的机械通气患者。
  • 纳入标准为需要机械通气的中度或重度COVID-19诱导的呼吸衰竭。

处置流程与药物剂量

  • 异体间充质干细胞2百万细胞/kg,静脉输注两次,联合标准治疗;对照为假输注。
  • 主要终点为30天死亡率;关键次要终点为60天内无呼吸机生存(秩分析,计入死亡和退出)。

研究设计与关键结果

  • 随机试验,计划入组300例,第三次中期分析时因预设死亡率降低(从40%至23%)不太可能达到而停止入组,实际n=222。
  • 30天死亡率:细胞组37.5%(42/112)vs 对照组42.7%(47/110),RR 0.88(95%CI 0.64-1.21;P=0.43)。
  • 60天内无呼吸机生存天数中位秩:细胞组117.3(IQR 60.0-169.5)vs 对照组102.0(IQR 54.0-162.5),无显著差异。
  • 30天ARDS缓解或改善:细胞组49.0%(51/104)vs 对照组43.4%(46/106),OR 1.36(95%CI 0.57-3.21)。
  • 无输注相关毒性;30天总体严重不良事件两组相似。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 局限:试验因预设死亡率降低不太可能达到而提前停止入组(n=222/计划300),可能影响统计效能。

对床旁实践的改变

  • 对于COVID-19相关中重度ARDS机械通气患者,异体间充质干细胞两次输注(2百万细胞/kg)安全,但未改善30天生存或60天无呼吸机生存。
  • 作者结论:间充质干细胞虽安全,但未改善30天生存或60天无呼吸机天数。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: There are limited therapeutic options for patients with coronavirus disease (COVID-19)-related acute respiratory distress syndrome with inflammation-mediated lung injury. Mesenchymal stromal cells offer promise as immunomodulatory agents. Objectives: Evaluation of efficacy and safety of allogeneic mesenchymal cells in mechanically-ventilated patients with moderate or severe COVID-19-induced respiratory failure. Methods: Patients were randomized to two infusions of 2 million cells/kg or sham infusions, in addition to the standard of care. We hypothesized that cell therapy would be superior to sham control for the primary endpoint of 30-day mortality. The key secondary endpoint was ventilator-free survival within 60 days, accounting for deaths and withdrawals in a ranked analysis. Measurements and Main Results: At the third interim analysis, the data and safety monitoring board recommended that the trial halt enrollment as the prespecified mortality reduction from 40% to 23% was unlikely to be achieved (n = 222 out of planned 300). Thirty-day mortality was 37.5% (42/112) in cell recipients versus 42.7% (47/110) in control patients (relative risk [RR], 0.88; 95% confidence interval, 0.64-1.21; P = 0.43). There were no significant differences in days alive off ventilation within 60 days (median rank, 117.3 [interquartile range, 60.0-169.5] in cell patients and 102.0 [interquartile range, 54.0-162.5] in control subjects; higher is better). Resolution or improvement of acute respiratory distress syndrome at 30 days was observed in 51/104 (49.0%) cell recipients and 46/106 (43.4%) control patients (odds ratio, 1.36; 95% confidence interval, 0.57-3.21). There were no infusion-related toxicities and overall serious adverse events over 30 days were similar. Conclusions: Mesenchymal cells, while safe, did not improve 30-day survival or 60-day ventilator-free days in patients with moderate and/or severe COVID-19-related acute respiratory distress syndrome.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bowdish ME, Barkauskas CE, Overbey JR, et al. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19. Am J Respir Crit Care Med. 2023. PMID: 36099435. doi:10.1164/rccm.202201-0157OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。